Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
2.570
0.00 (0.00%)
At close: Apr 3, 2025, 4:00 PM
2.508
-0.062 (-2.41%)
Pre-market: Apr 4, 2025, 4:00 AM EDT
Vivos Therapeutics Employees
As of December 31, 2023, Vivos Therapeutics had 123 total employees, including 114 full-time and 9 part-time employees. The number of employees decreased by 40 or -24.54% compared to the previous year.
Employees
123
Change (1Y)
-40
Growth (1Y)
-24.54%
Revenue / Employee
$122,203
Profits / Employee
-$90,537
Market Cap
15.14M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 123 | -40 | -24.54% |
Dec 31, 2022 | 163 | -4 | -2.40% |
Dec 31, 2021 | 167 | 69 | 70.41% |
Dec 31, 2020 | 98 | 14 | 16.67% |
Dec 31, 2019 | 84 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VVOS News
- 3 days ago - Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update - GlobeNewsWire
- 6 days ago - Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - GlobeNewsWire
- 3 months ago - Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call - GlobeNewsWire
- 6 months ago - Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association - GlobeNewsWire
- 7 months ago - Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - GlobeNewsWire